$117.39
0.940.81%
Ult. Agg.: Oct 21, 2:38 PM
$116.27
-0.18-0.15%
Corcept Therapeutics (CORT) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Corcept Therapeutics (CORT) ha pubblicato l'ultima guidance il luglio 29, 2026 per fiscal year 2026. La società ha previsto un fatturato pari a $1.1B - $1.2B per il periodo.
Rispetto alle previsioni precedenti, Corcept Therapeutics ha modificato le sue previsioni di fatturato da un intervallo precedente di .
Corcept Therapeutics ha pubblicato {{revenueDirection}} aggiornamenti delle previsioni tra il {{revenuePriorRange}} e il Corcept Therapeutics. 19
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.02 | $-0.17 | $0.31 | $0.15 |
| Actual | $0.36 | $-0.30 | $0.20 | $0.16 |
| Surprise | +1700.0% | -76.5% | -35.5% | +6.67% |
| Revenue | ||||
| Estimate | $219.3M | $183.8M | $254.7M | $218.8M |
| Actual | $256.1M | $164.9M | $202.1M | $207.6M |
| Surprise | +16.8% | -10.3% | -20.6% | -5.10% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.81 | $1.13 | $0.43 | $0.78 |
| Revenue | ||||
| Consensus | $334.9M | $389.9M | — | — |
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q2 | Jul 29, 2026 | $0.36 | $0.02 | 1700.0 % |
| Q1 | Apr 30, 2026 | $-0.30 | $-0.17 | -76.5 % |
| Q4 | Feb 24, 2026 | $0.20 | $0.31 | -35.5 % |
| Q3 | Nov 4, 2025 | $0.16 | $0.15 | 6.67 % |
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q2 | Jul 29, 2026 | $256.15M | $219.32M | 16.8 % |
| Q1 | Apr 30, 2026 | $164.90M | $183.78M | -10.3 % |
| Q4 | Feb 24, 2026 | $202.13M | $254.72M | -20.6 % |
| Q3 | Nov 4, 2025 | $207.64M | $218.79M | -5.10 % |